Management of perioperative hypertensive urgencies with parenteral medications

Journal of Hospital Medicine

Volumn 5, Issue 2, 2010, Pages

  Ahuja, Kartikya ^a   Charap, Mitchell H ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertension; Hypertensive urgency; Operative; Parenteral; Surgery

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLONIDINE; ENALAPRILAT; FENOLDOPAM; HYDRALAZINE; LABETALOL; METOPROLOL; NICARDIPINE; NITROPRUSSIDE SODIUM;

ANGIONEUROTIC EDEMA; ARTERY CATHETER; ARTIFICIAL VENTILATION; BLOOD PRESSURE REGULATION; BRONCHOSPASM; COMORBIDITY; CONTINUOUS INFUSION; DIZZINESS; DROWSINESS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHEMA; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; INTENSIVE CARE UNIT; MEDLINE; NAUSEA; PANCREATITIS; PARESTHESIA; PATIENT MONITORING; PERIOPERATIVE HYPERTENSION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; INFUSIONS, PARENTERAL; PERIOPERATIVE CARE;

EID: 76149093862     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.629     Document Type: Review

References (56)

1. Prys-Roberts C, Meloche R, Foex P. Studies of anaesthesia in relation to hypertension. I. Cardiovascular responses of treated and untreated patients. Br J Anaesth. 1971;43(2):122-137.
2. Prys-Roberts C, Greene LT, Meloche R, et al. Studies of anaesthesia in relation to hypertension. II. Haemodynamic consequences of induction and endotracheal intubation. Br J Anaesth. 1971;43(6):531-547.
3. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297(16): 845-850.
4. Detsky AS, Abrams HB, Forbath N, et al. Cardiac assessment for patients undergoing noncardiac surgery. A multifactorial clinical risk index. Arch Intern Med. 1986;146(11):2131-2134.
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
6. Prys-Roberts C, Meloche R. Management of anesthesia in patients with hypertension or ischemic heart disease. Int Anesthesiol Clin. 1980;18(4): 181-217.
7. Goldman L, Caldera DL. Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology. 1979;50(4):285-292.
8. Weksler N, Klein M, Szendro G, et al. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery? J Clin Anesth. 2003;15(3):179-183.
9. Wolfsthal SD. Is blood pressure control necessary before surgery? Med Clin North Am. 1993;77(2):349-363.
10. Gal TJ, Cooperman LH. Hypertension in the immediate postoperative period. Br J Anaesth. 1975;47(1):70-74.
11. Kaplan NM. Management of hypertensive emergencies. Lancet. 12 1994; 344(8933):1335-1338.
12. Shayne PH, Pitts SR. Severely increased blood pressure in the emergency department. Ann Emerg Med. 2003;41(4):513-529.
13. Zeller KR, Von Kuhnert L, Matthews C. Rapid reduction of severe asymptomatic hypertension. A prospective, controlled trial. Arch Intern Med. 1989;149(10):2186-2189.
14. Strandgaard S, Paulson OB. Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens. 1989;2:(6 pt 1):486-492.
15. Reams GP, Lau A, Messina C, et al. Efficacy, electrocardiographic and renal effects of intravenous diltiazem for essential hypertension. Am J Cardiol. 1987;60(17):78I-84I.
16. Frishman WH, Weinberg P, Peled HB, et al. Calcium entry blockers for the treatment of severe hypertension and hypertensive crisis. Am J Med. 1984;77:(2B):35-45.
17. Chun G, Frishman WH. Rapid-acting parenteral antihypertensive agents. J Clin Pharmacol. 1990;30(3):195-209.
18. Bauer JH, Reams GP. The role of calcium entry blockers in hypertensive emergencies. Circulation. 1987;75(6 pt 2):V174-180.
19. Schaller MD, Nussberger J, Waeber B, et al. Transdermal clonidine therapy in hypertensive patients. Effects on office and ambulatory recorded blood pressure values. JAMA. 1985;253(2):233-235.
20. Ghignone M, Calvillo O, Quintin L. Anesthesia and hypertension: the effect of clonidine on perioperative hemodynamics and isoflurane requirements. Anesthesiology. 1987;67(1):3-10.
21. Stuhmeier KD, Mainzer B, Cierpka J, et al. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Anesthesiology. 1996;85(4):706-712.
22. Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology. 2004;101(2):284-293.
23. Pasternack PF, Grossi EA, Baumann FG, et al. Beta blockade to decrease silent myocardial ischemia during peripheral vascular surgery. Am J Surg. 1989;158(2):113-116.
24. Magnusson J, Thulin T, Werner O, et al. Haemodynamic effects of pretreatment with metoprolol in hypertensive patients undergoing surgery. Br J Anaesth. 1986;58(3):251-260.
25. Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996;335(23):1713- 1720.
26. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341(24):1789-1794.
27. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol. 2007;50(17):e159-e241.
28. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100(10):1043-1049.
29. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371(9627):1839-1847.
30. Jackson EK, Campbell WB. Inhibition of angiotensin II potentiation of sympathetic nerve activity by beta-adrenergic antagonists. Hypertension. 1980;2(1):90-96.
31. Yorukoglu D, Goktug A, Alanoglu Z, et al. Comparison of intravenous metoprolol, verapamil and diltiazem on the attenuation of haemodynamic changes associated with tracheal extubation. Eur J Anaesthesiol. 1999;16(7):462-467.
32. Felding M, Jakobsen CJ, Cold GE, et al. The effect of metoprolol upon blood pressure, cerebral blood flow and oxygen consumption in patients subjected to craniotomy for cerebral tumours. Acta Anaesthesiol Scand. 1994;38(3):271-275.
33. Wilson DJ, Wallin JD, Vlachakis ND, et al. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med. 1983;75:(4A):95-102.
34. Morel DR, Forster A, Suter PM. I.V. labetalol in the treatment of hypertension following coronary-artery surgery. Br J Anaesth. 1982;54(11): 1191-1196.
35. Leslie JB, Kalayjian RW, Sirgo MA, et al. Intravenous labetalol for treatment of postoperative hypertension. Anesthesiology. 1987;67(3):413-416.
36. Orlowski JP, Shiesley D, Vidt DG, et al. Labetalol to control blood pressure after cerebrovascular surgery. Crit Care Med. 1988;16(8):765-768.
37. Lopez-Jaramillo P, Narvaez M, Calle A, et al. Cyclic guanosine 30,50 monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol. 1996;103(1):33-38.
38. Ludden TM, Shepherd AM, McNay JL Jr, et al. Effect of intravenous dose on hydralazine kinetics after administration. Clin Pharmacol Ther. 1983; 34(2):148-152.
39. Armario P, Hernandez del Rey R, Pardell H. Adverse effects of direct-acting vasodilators. Drug Saf. 1994;11(2):80-85.
40. Skydell JL, Machleder HI, Baker JD, et al. Incidence and mechanism of post-carotid endarterectomy hypertension. Arch Surg. 1987;122(10): 1153-1155.
41. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Bmj. 2003;327(7421): 955-960.
42. Haas AR, Marik PE. Current diagnosis and management of hypertensive emergency. Semin Dial. 2006;19(6):502-512.
43. Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med. 1995;155(20):2217-2223.
44. De Marco T, Daly PA, Liu M, et al. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. J Am Coll Cardiol. 1987;9(5):1131-1138.
45. Paulson OB, Jarden JO, Godtfredsen J, et al. Cerebral blood flow in patients with congestive heart failure treated with captopril. Am J Med. 1984;76:(5B):91-95.
46. Evans RR, Henzler MA, Weber EM, et al. The effect of intravenous enalaprilat (MK-422) administration in patients with mild to moderate essential hypertension. J Clin Pharmacol. 1987;27(5):415-418.
47. Rosenman DJ, McDonald FS, Ebbert JO, et al. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period. J Hosp Med. 2008;3(4):319-325.
48. Curry SC, Arnold-Capell P. Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors. Crit Care Clin. 1991;7(3):555-581.
49. Fruncillo RJ, Rocci ML, Jr., Vlasses PH, et al. Disposition of enalapril and enalaprilat in renal insufficiency. Kidney Int Suppl. 1987;20:S117-122.
50. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316(23):1429-1435.
51. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952-1961.
52. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 28 2005; 353(4):349-361.
53. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet. 2005;366(9497):1622-1632.
54. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J. 2001; 141(1):148-153.
55. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007. [No authors listed]
56. Lette J, Waters D, Bernier H, et al. Preoperative and long-term cardiac risk assessment. Predictive value of 23 clinical descriptors, 7 multivariate scoring systems, and quantitative dipyridamole imaging in 360 patients. Ann Surg. 1992;216(2):192-204.